

**THE UNITED NATIONS GLOBAL COMPACT  
COMMUNICATIONS ON PROGRESS  
PFIZER INC  
May 2005-December 2006**

In 2002 Pfizer Inc signed the United Nations Global Compact. Pfizer is still the only U.S. pharmaceutical company to participate in the Compact.

Pfizer's commitment to advancing the 10 principles is publicly affirmed in our Corporate Citizenship Report, surveys, speeches, panel sessions, websites, book chapters and brochures. Internally, we affirm the principles in our global Code of Business Conduct, colleague training manuals, policy discussions and colleague forums such as our global company online newsletter.

**External Forums**

**2005 Corporate Citizenship Report** In November 2005 Pfizer published its first Corporate Citizenship Report. This report focused on Pfizer's business operations and corporate citizenship priorities. In a section called 'Policies and Programs for a Responsible Business' on page 4, Pfizer described the Global Compact and actions that Pfizer has taken to advance the principles. This section offers a link to the Global Compact website and also refers readers seeking more information to sections of Pfizer's website that details our commitment and actions.

[http://pfizer.com/pfizer/subsites/corporate\\_citizenship/report/pfizer\\_citizenship.jsp](http://pfizer.com/pfizer/subsites/corporate_citizenship/report/pfizer_citizenship.jsp)

**UN Global Compact Summit in Shanghai China** In November 2005, CEO and Chairman Jeff Kindler, then Vice Chairman and General Counsel, was a keynote speaker on the topic of "The Global Compact: An Alliance for a Sustainable Global Economy."

**Article for Business for Social Responsibility Magazine 'From Piecemeal Programming to Universal Thinking: Pfizer's Global Citizenship Framework'** In this article, published in November 2005, Mr. Kindler cites Pfizer joining the UN Global Compact as signaling our commitment to social responsibilities and driving our actions company-wide.

**Transnational Corporations China Forum in Beijing** In 2006, Mr. Kindler spoke on "Pfizer's Global Corporate Citizenship: Towards a Healthy Society and Enterprise" before an audience of 500 business, government and academic leaders – mostly Chinese nationals. His speech included the Global Compact.

**Internal Communications**

**Pfizer Code of Conduct & Compliance Training** Pfizer requires all colleagues to master the Pfizer Policies on Business Conduct. This mandatory exercise ensures that all employees are informed and accountable to Corporate standards. The Global Compact and Pfizer's commitment to its principles are explained on page 32. Please see:

[http://www.pfizer.com/download/investors/corporate/business\\_conduct\\_policies\\_summary\\_2003.pdf](http://www.pfizer.com/download/investors/corporate/business_conduct_policies_summary_2003.pdf)

**System:**

The following chart shows the breadth of Pfizer's Corporate Citizenship system based on the UN Global Compact Principles – along with program impacts and external evaluations. This chart illustrates examples of Pfizer's **Action** & **Performance** for each of the Global Compact's four main categories: Human Rights, Labor, Environment & Anti-Corruption:

GLOBAL COMPACT PRINCIPLES Definition	GLOBAL COMPACT Expanded Definition	<u>ACTION</u>	<u>PERFORMANCE</u>
<b>ALL 10 PRINCIPLES</b>		<p><b><u>CONTEXT:</u></b> Pfizer began implementing the UN Global Compact by creating a global cross-divisional team of more than two dozen management-level employees who came from all operating divisions representing many different functions — ranging from research and development to investor relations.</p> <p>The team established goals, collected data and compared Pfizer's policies and practices to the Compact's Principles. Pfizer developed a plan educate employees and improve company performance. Today Pfizer's Summary of Policies on Business Conduct, which is mandatory reading for all Pfizer employees around the world, includes information on the Global Compact to strengthen corporate citizenship at a local and global level.</p>	<p><b>-Pfizer's Summary of Policies on Business Conduct</b> has been translated into 35 languages. <b>Pfizer employees are tested on the content.</b></p>
<b>HUMAN RIGHTS</b>			
<p><b>Principle #1</b></p> <p>Business should support and respect the protection of internationally proclaimed human rights within their</p>	<p>To ensure the companies are not complicit in human rights violations, either direct, beneficial or silent, emphasis must be placed on growth of a</p>	<p><b><u>CONTEXT:</u></b> In the pharmaceutical industry, human rights issues in the public domain range from compliance with the rule of law to improving access to medicine.</p> <p><b><u>STAKEHOLDER ENGAGEMENT:</u></b> In 2006 a cross-divisional Pfizer team met with key NGOs and socially responsible investors, concerned with human rights and improving access to</p>	<p><b>-Please see</b> <a href="http://www.business-humanrights.org">www.business-humanrights.org</a></p>

<p>sphere of influence</p> <p><b>Principle # 2</b></p> <p>“Business should make sure their own corporations are not complicit in human rights abuses”</p>	<p>civil society, transparency and accountability</p>	<p>medicines in the developing world, to discuss Pfizer’s policies and actions. These groups included Oxfam Great Britain, Oxfam America and the Interfaith Center on Corporate Responsibility, among others. Pfizer also engaged in postings on <a href="http://www.business-humanrights.org">www.business-humanrights.org</a>.</p> <p>In 2005 Pfizer, with help from global stakeholder research firm GlobeScan, conducted interviews regarding perceptions of Pfizer and the pharmaceutical industry. GlobeScan interviewed 349 healthcare opinion leaders in China, Great Britain, Japan, Mexico, South Africa and the U.S. representing four stakeholder groups: government, health policymakers, NGOs and multilateral organizations.</p> <p><b><u>ACCESS TO MEDICINES:</u></b> To improve <b>access to medicine and health</b> for those who need it most, we are building our access programs around 5 paradigms:</p> <ul style="list-style-type: none"> <li>• Advancing Research and Development</li> <li>• Improving Access to Medicine</li> <li>• Building Healthcare System Capacities</li> <li>• Teaching Disease Management</li> <li>• Managing Disaster Relief &amp; Recovery</li> </ul> <p><i><u>Advancing Research and Development Programs:</u></i></p> <p>-Pfizer partnered with the World Health Organization to <b>provide access to Pfizer’s library of medicinal compounds</b>, the world’s largest, and brings scientists from developing countries into Pfizer’s laboratories for <b>training in drug discovery techniques</b>. The collaboration with <b>The Special Program for Research and Training in Tropical Diseases of the WHO (WHO/TDR)</b> is part of a new effort to link the research resources of a major pharmaceutical company to a global network of discovery research, and speed the search for new drugs to combat some of the world's most deadly parasitic diseases. Under the arrangement, <b>scientists affiliated with the WHO/TDR-</b></p>	<p>-<b>Results</b> from this research, specifically the <b>key strengths and weaknesses of the pharmaceutical industry</b> are available in our corporate citizenship report at <a href="http://pfizer.com/pfizer/subsites/corporate_citizenship/report/stakeholder.jsp">http://pfizer.com/pfizer/subsites/corporate_citizenship/report/stakeholder.jsp</a></p> <p>-“<b>This agreement with Pfizer is a step forward in expanding worldwide capacity in tropical disease research</b>, because it enhances access to research tools for developing country researchers and expands access to large numbers of compounds for screening to identify new leads,” said <b>Dr Robert Ridley, director of WHO/TDR</b> <a href="http://mediaroom.pfizer.com/index.php?s=press_releases&amp;item=114">http://mediaroom.pfizer.com/index.php?s=press_releases&amp;item=114</a></p>
---	---	---	---

		<p><b>sponsored Compound Evaluation Network are testing thousands of compounds from the Pfizer library.</b> Developing country researchers supported by Medicinal Chemistry Network are working with scientists at Pfizer's laboratories in Sandwich, UK, to further evaluate those with the greatest potential to be developed into new medicines for parasitic disease treatment and prevention.</p> <p>- In 2006, Pfizer partnered with the <b>National Institutes of Health</b> and biotech companies Perlegen and Affymetrix to launch an initiative aimed at <b>accelerating research in applying the human genome map to better patient health.</b> Pfizer seeded <b>\$5 million to set up the management structure</b> and <b>\$15 million for laboratory studies</b> to determine the genetic contributions to five most common diseases.</p> <p><i>Improving Access to Medicine Programs:</i>  <b>-Pfizer Helpful Answers</b> is a comprehensive US program that helps US patients without prescription medicine coverage to identify the Pfizer medicine savings program that is right for them. <b>Sharing the Care, Connection to Care, Pfizer Pfriends and Programs for Individual Medicines</b> are all components of Pfizer's comprehensive outreach to the uninsured in the US by partnering with local health centers, physicians and the government. For example, Pfizer's <b>Sharing the Care</b> donates its most advanced medicines to low income, uninsured patients through community, migrant and homeless health centers throughout the country. Pfizer's <b>Connection to Care</b> provides free medications to eligible uninsured patients. For more program information please see <a href="http://www.pfizerhelpfulanswers.com/">http://www.pfizerhelpfulanswers.com/</a></p>	<p>-"We now stand on the threshold of creating a future that will <b>revolutionize the practice of medicine</b> by predicting disease, developing more precise therapies and, <b>ultimately, pre-empting the emergence of disease.</b>" <b>Elias A. Zerhouni, M.D., Director of the NIH.</b>  <a href="http://www.genome.gov/1751672">http://www.genome.gov/1751672</a>  <u>2</u></p> <p>-In 2006 Pfizer's Helpful Answers™ program helped <b>over 1,778,000 patients</b> in the U.S. fill <b>over 10,440,000 prescriptions</b> and the programs have saved patients <b>more than \$941,064,000.</b></p>
--	--	---	--

		<p><u><i>Building Healthcare System Capacities Programs:</i></u></p> <p><b>-Infectious Diseases Institute (IDI)</b> Pfizer and the Pfizer Foundation supported the building of a regional treatment and training institute in Kampala, Uganda to strengthen local and regional capacity in HIV/AIDS care. Partners in this initiative include: Makerere University, the Academic Alliance Foundation for AIDS Care and Prevention in Africa, San Francisco AIDS Foundation, the Infectious Diseases Society of America, and The AIDS Support Organization (TASO). For more program information please see <a href="http://www.pfizer.com/pfizer/subsites/corporate_citizenship/report/infectious.jsp">http://www.pfizer.com/pfizer/subsites/corporate_citizenship/report/infectious.jsp</a></p> <p>-Pfizer's <b>Global Health Fellows Program</b> deploys qualified Pfizer colleagues for short and long term assignments assisting NGOs working to fight HIV/AIDS and other diseases in the developing world, similar to a medical Peace Corps. For more program information please see <a href="http://www.pfizer.com/subsites/philanthropy/caring/employee.commitment.fellows.html">http://www.pfizer.com/subsites/philanthropy/caring/employee.commitment.fellows.html</a></p> <p><b>- Closing the Malaria Treatment Gap</b> In 2006 Pfizer made a 5 year-\$15 million commitment to the Clinton Global Initiative to help (i) to increase the percentage of patients who seek proper malaria care and (ii) to improve medicines delivery to, and enhance the effectiveness of the informal sector as the most important infrastructure component of antimalarial delivery. The program will begin as a pilot in Ghana, Senegal and Kenya. The anticipated launch of the program is April 2007.</p>	<p>- Since 2004 the IDI has delivered care to more than <b>19,000 patients</b> and trained more than <b>1,000 healthcare providers</b> from <b>22 African countries</b>.</p> <p>- Since 2003 <b>over 115 Global Health Fellows</b> have served as physicians, epidemiologists, nurses, educators, and business consultants all over the world.</p> <p><b>-Metrics are currently under development</b> but may include:</p> <ul style="list-style-type: none"> <li>• % increase in number of caretakers seeking treatment for feverish child</li> <li>• % of children who took anti-malarial drugs</li> <li>• % of informal outlet providers who supply adequate treatment</li> <li>• % of informal outlet providers who provide correct diagnosis, malaria treatment compliance information and referrals (in case of severe malaria)</li> </ul>
--	--	---	--

		<p><u>Teaching Disease Management Programs:</u></p> <p>- <b>Pfizer's Florida: A Healthy State</b> is aimed at chronically ill, high-risk Medicaid patients with asthma, diabetes, congestive heart failure and/or high blood pressure. The program employs a team of 55 care managers, trained by Pfizer, to help patients adhere to prescribed treatment plans, follow an appropriate diet plan, stop smoking, moderate their use of alcohol and monitor their own health. For more programmatic information please see <a href="http://www.floridahealthy.org/">http://www.floridahealthy.org/</a></p> <p>-<b>Green Ribbon Health</b> is a three-year joint pilot program between Pfizer Health Solutions and Humana in a nine-county region in Central Florida. This was one of nine contracts awarded by the Centers for Medicare &amp; Medicaid Services (CMS) to provide 20,000 selected Medicare beneficiaries with diabetes and/or congestive heart failure broad access to coordinated health care services that improve health and preserve independence while reducing health care costs. <a href="http://www.pfizerhealthsolutions.com/ourprojects/projectsmedicare_greenribbon.asp">http://www.pfizerhealthsolutions.com/ourprojects/projectsmedicare_greenribbon.asp</a></p> <p>-Pfizer's <b>Diflucan Partnership Program</b> is a public-private partnership that donates Diflucan® (fluconazole) for two opportunistic infections associated with HIV/AIDS in developing countries, and trains health care providers. For more program information please see <a href="http://www.pfizer.com/subsites/philanthropy/caring/global.health.hiv.diflucan.html">http://www.pfizer.com/subsites/philanthropy/caring/global.health.hiv.diflucan.html</a></p>	<p>- Between 2001 and 2003 Florida achieved medical cost <b>savings of \$41.9 million</b> by increasing out-patient doctor visits and decreasing emergency visits. <i>(validated by a third party organization, Medical Scientists Inc).</i> During this time nearly <b>150,000 patients</b> have received educational support and access to new health services.</p> <p>-Metrics will be available on this program, measuring <b>better health outcomes and medical cost savings.</b></p> <p>- As of October 2006, the <b>Diflucan Partnership Program</b> has donated more than <b>\$471 million in medicine to 47 countries in more than 1,000 sites in Africa, Asia, the Caribbean and Latin America,</b> and <b>treated more than 110,000 patients.</b> More than <b>20,000 health care providers have been trained</b> in the diagnosis and treatment of fungal opportunistic infections.</p>
--	--	---	---

		<p>-Pfizer's <b>International Trachoma Initiative (ITI)</b> in partnership with the World Health Organization (WHO), aims to eliminate trachoma, the leading cause of preventable blindness, by donating the antibiotic Zithromax®, in combination with public health education. The WHO SAFE Strategy, which is a combination of antibiotic face washing, environmental access to clean water and surgery when necessary, is used as the programmatic approach for the treatment and prevention of trachoma. The creation of ITI was a vehicle for scalable implementation of the SAFE strategy. For more program information please see <a href="http://www.trachoma.org/home.asp">http://www.trachoma.org/home.asp</a></p> <p>-<b>Southern HIV/AIDS Prevention Initiative</b> launched in 2003, will direct \$6 million over three years to fund innovative HIV/AIDS prevention programs in multi-cultural communities in nine southern states: Alabama, Florida, Georgia, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee or Texas. For more program information please see <a href="http://www.pfizer.com/subsites/philanthropy/caring/global.health.hiv.southern.html">http://www.pfizer.com/subsites/philanthropy/caring/global.health.hiv.southern.html</a></p>	<p>-The ITI has given <b>40 million treatments</b> of Pfizer's antibiotic, Zithromax (azithromycin) to patients in <b>13 countries</b>, and <b>trained thousands of health care professionals</b> who, in turn, have completed <b>239,000 surgeries</b> to treat advanced cases of trachoma since 1998.</p> <p>-Pfizer is supporting a network of <b>more than 55 innovative HIV/AIDS prevention programs</b>. From this investment, <b>more than 1,000 people have been trained as peer educators, health advisors and volunteers</b>. <b>Thousands of people have received needed support</b> through community outreach programs and referrals for HIV treatment and counseling.</p> <p>-PR News awards Pfizer's HIV/AIDS initiative, <b>Women Like You! The Power of Partnership (WLY)</b>, the <b>Corporate Social Responsibility Award</b> in the Community Affairs category, which recognizes leadership in developing <b>innovative corporate social-outreach programs</b>.</p>
--	--	---	---

		<p><u><i>Managing Disaster Relief &amp; Recovery Programs:</i></u></p> <p>-- Pfizer's immediate and comprehensive response to the needs of the <b>2004 Tsunami</b> survivors included the donation of cash, medicines and expertise in logistics, health and public policy. Pfizer coordinated with colleagues across the globe to partner with local and global organizations at all stages of the relief effort. The Pfizer Disaster Management Program is unique in that Pfizer addressed mental as well as physical health needs, preventative education as well as disease management, logistical as well as healthcare capacity building.</p> <p><a href="http://www.pfizer.com/pfizer/subsites/corporate_citizenship/report/manufacturing.jsp">http://www.pfizer.com/pfizer/subsites/corporate_citizenship/report/manufacturing.jsp</a></p> <p>--Pfizer's learning from the tsunami informed our response to <b>Hurricanes Katrina and Rita</b> which hit the Gulf coast region of the southern U.S. in August and September 2005. Pfizer partnered with community health centers, hospitals and pharmacies to provide emergency medications and consumer health products to displaced people and sent teams of colleagues with expertise in supply chain management to Louisiana, Mississippi and Texas to organize safe distribution of medications.</p> <p><a href="http://www.pfizer.com/pfizer/subsites/corporate_citizenship/report/manufacturing.jsp">http://www.pfizer.com/pfizer/subsites/corporate_citizenship/report/manufacturing.jsp</a></p> <p>--Pfizer, in partnership with other companies including GE, Citigroup, Xerox and UPS, the Committee to Encourage Corporate Philanthropy, USAID and government officials, formed the <b>South Asia Earthquake Relief Fund (SAERF)</b>. The SAERF goals are to: collect and manage cash donations to the fund, provide grants for relief and reconstruction, and communicate the fundraising effort and accomplishments.</p>	<p>-Pfizer <b>donated \$60 million</b> in cash and medicines to the 2004 Tsunami and 2005 Hurricane relief efforts, sent skilled volunteers and provided mental and physical health resources. They provided <b>medical, engineering, environmental and supply-chain management expertise</b> to health officials, relief organizations, the UN, UNICEF and the WHO.</p> <p>-In 2005 SAERF distributed <b>\$4.5 million</b> to provide immediate disaster relief to earthquake-affected individuals. In 2006 the Fund earmarked money for reconstruction. The SAERF has issued a <b>\$12 million grant</b> to the Pakistan Poverty Alleviation Fund focused on reconstruction of <b>35 schools and health care centers</b>.</p> <p><b>-The International Rescue Committee</b> presented Pfizer with</p>
--	--	--	---

			<p>its <b>Corporate Responsibility Award</b> at its Freedom Award Dinner in November, 2006 to recognize the longstanding partnership between the two organizations. Pfizer has collaborated with IRC on a variety of causes, most recently on the response to the devastating earthquake in Pakistan and the tsunami that struck Southeast Asia in 2004.</p>
<p><b>LABOR</b></p>			
<p><b>Principle #3</b> Businesses should uphold the freedom of association and the effective recognition of the right to collective bargaining</p> <p><b>Principle #4</b> Businesses should uphold the elimination of all forms of forced and compulsory labor</p> <p><b>Principle #5</b> Businesses should uphold the effective abolition of child labor</p> <p><b>Principle #6</b></p>	<p>Businesses should safeguard against direct and indirect forms of discrimination, as discrimination restricts the labor pool and slows economic growth for society.</p> <p>Companies can institute barrier to discrimination in the workplace and encourage communities to build a culture of tolerance.</p>	<p><b>CONTEXT:</b> In the pharmaceutical industry, employees' knowledge, skills, innovation and commitment are a company's greatest assets.</p> <p>Our <b>Pfizer values</b> are at the heart of our business. They are: Integrity, Respect for People, Customer Focus, Community, Innovation, Teamwork, Performance, Leadership, and Quality. These are <b>reinforced through colleague performance evaluations linked to compensation.</b></p> <p>Pfizer recognizes that progressive labor policies are good business practices, especially for a global company. We uphold laws and nurture a work environment that welcomes diversity and fair treatment in the recruiting process and the workplace.</p> <p>In additional to many equal opportunity programs, our social responsibility highlights two programs: our <u>global policy on HIV &amp; AIDS in the workplace</u> and our <u>diversity affinity groups</u>.</p> <p>Pfizer instituted a unique <b>global policy on HIV &amp; AIDS in the</b></p>	<p>-In 2005 Pfizer appointed a <b>Vice President of Diversity and Inclusion</b> who is leading the design and implementation of results-oriented global diversity and inclusion.</p>

<p>“Businesses should uphold the elimination of discrimination in respect of employment and occupation.”</p>		<p><b>workplace</b>, addressing issues of non-discrimination, awareness, prevention and health support. Pfizer’s HIV &amp; AIDS programming is holistic in that it addresses not only discrimination, but awareness, prevention and health support as well – even in cultures where AIDS is a taboo.</p> <p>In 2005 Pfizer China was the first multinational pharmaceutical company in China to issue a corporate HIV/AIDS Workplace Policy that guarantees a work environment free from harassment and discrimination for colleagues living with HIV/AIDS.</p> <p>While the programs are locally based and designed to meet local conditions, the overarching policy of HIV/AIDS applies to all employees of the Company and its subsidiaries.</p> <p>- A partnership among Pfizer <b>Animal Health, the Pfizer Foundation and The Resource Foundation</b> is helping eradicate child labor, combat malnutrition and increase household income in some of Latin America’s most impoverished regions. The program provides families with a source of additional income, raising goats, in place of supplemental wages often earned by children.</p> <p>-Pfizer’s <b>Diversity Affinity Groups</b> have won multiple awards for their approach to addressing minority, gender, and cultural discrimination.</p>	<p>- <b>For the 3<sup>rd</sup> consecutive year, Pfizer received in 2006 a perfect score of 100 percent in the Human Rights Campaign Foundation's Corporate Equality Index</b> recognizing fair and equitable workplace policies. <a href="http://www.hrc.org/Template.cfm?Section=Get_Informed2&amp;Template=/ContentManagement/ContentDisplay.cfm&amp;ContentID=33909">http://www.hrc.org/Template.cfm?Section=Get_Informed2&amp;Template=/ContentManagement/ContentDisplay.cfm&amp;ContentID=33909</a></p> <p>-The program has helped more than <b>2,000 families in Argentina, Brazil, Chile, Costa Rica, Mexico and Venezuela</b> enhance their technical skills and animal husbandry to increase incomes and improve quality of life. For example, in Brazil, investment in 4 years of this program has led to a <b>40% reduction in child malnutrition rates</b> and a <b>33% increase in income</b> of participating families in the region. More than <b>1,600 children now attend school</b> regularly in the region.</p>
--	--	--	---

		<p>Pfizer currently has <b>17 networks focused on the interests and needs of Asians, African-Americans, Hispanics, Women and Gays and Lesbians (LGBT)</b>. Their goal is to provide educational opportunity to members, support community outreach and assist Pfizer in achieving its corporate mission. They are involved in recruiting and on-boarding and providing support mechanisms for members.</p>	<p><i>A sample of 2006 Diversity Programming Awards follows:</i>                  -Pfizer was named to the list of <b>Fortune 100 Top Employers for Women MBAs</b>                  -One of the <b>100 Best Companies for Working Mothers</b> - Working Mother Magazine</p> <p>A more complete list of awards can be found at <a href="http://pfizer.com/pfizer/are/mn_about_accolades.jsp">http://pfizer.com/pfizer/are/mn_about_accolades.jsp</a></p>
<p><b>ENVIRONMENT</b></p>			
<p><b>Principle #7</b>                  Businesses should support a precautionary approach to environmental challenges</p> <p><b>Principle #8</b>                  Businesses should undertake initiatives to promote greater environmental responsibility</p> <p><b>Principle #9</b>                  “Businesses should encourage the development and</p>	<p>Businesses must develop and utilize “environmentally friendly”, or “environmentally sound” technology. Changes must be implemented at unit level, by means of manufacturing technique or materials, as well as at a strategic level through company policy, stakeholders, R&amp;D, and constant monitoring of environmental issues and initiatives.</p>	<p><b>CONTEXT</b>                  As a pharmaceutical company, the advancement of good health occurs not only through the innovation, production and distribution of medicines, but also through the creation and preservation of a healthy environment.</p> <p>Pfizer is dedicated to identifying emerging environmental issues relevant to the pharmaceutical and biotechnical industry and stakeholders and leading efforts to address them strategically and tactically through innovative policies and technology programs.</p> <p>Driven by Pfizer’s dynamic business environment, the global EHS community will seize opportunities to advance the efficiency and effectiveness of Pfizer’s EHS programs. To this end, EHS will focus on the following <b>six strategic imperatives</b>:</p> <ol style="list-style-type: none"> <li>1. Integrate EHS into business functions and product development</li> <li>2. Drive risk-based EHS decision making</li> <li>3. Capture opportunity and mitigate risk associated with sourcing</li> </ol>	

<p>diffusion of environmentally friendly technologies.”</p>		<ol style="list-style-type: none"> <li>4. Build the business and technical capabilities of EHS colleagues</li> <li>5. Shape a positive environment through selective stakeholder engagement</li> <li>6. Drive advantage through EHS performance</li> </ol> <p><b>PROGRAMS:</b> Pfizer’s <b>Climate Change and Energy Program</b> seeks to minimize the cost and operational restrictions arising from a carbon constrained environment, reduce Pfizer’s contribution to Greenhouse Gas (GHG) emissions, and facilitate Pfizer business and operational adaptation to the physical changes resulting from a warming global climate.</p> <p><b>Reduction of energy use</b> is achieved through implementation of both a Demand Side Management program (e.g., tracking and reporting of Pfizer’s energy use and worldwide GHG emissions, commitment to and monitoring of progress towards public company-wide goal) and Supply Side Energy Program (e.g., procurement of clean energy, completion of clean energy projects, declaration of and monitoring progress towards a public company-wide goal).</p> <p>To contribute to the world's efforts to reduce GHG emissions, Pfizer joined the <b>U.S. Environmental Protection Agency’s Climate Leaders program</b> (a voluntary industry-government partnership that encourages companies to develop long-term, comprehensive climate change strategies) in 2002 and set a company-wide goal to reduce CO<sub>2</sub> emissions by 35% per \$ million of sales by 2007 from the baseline year 2000. At the time, <b>Pfizer was one of the first Climate Leaders member companies to set a global goal.</b> In 2003, Pfizer complemented its strategy by adding a commitment to meet 35% of its global electricity needs by 2010 through the use of "clean" energy sources.</p> <p><a href="http://www.pfizer.com/ehs/environ/energy.html">http://www.pfizer.com/ehs/environ/energy.html</a></p> <p><b>Green Chemistry:</b> Pfizer has been at the forefront of developing and manufacturing drugs using environmentally-friendly Green Chemistry (GC) practices. By applying GC principles, Pfizer has</p>	<p>-On track to meeting <b>public goal</b> - in 2005 <b>achieved 31% reduction in CO<sub>2</sub></b> relative to revenue from 2000 baseline.</p> <p>-On track to meeting <b>public goal</b> – in 2005, <b>met 19% of electricity needs through clean energy technology</b> (co-generation, hydro, renewable).</p> <p>-October 2006, IChemE recognized Pfizer for <b>Green Chemistry practices for Lyrica® and Vfend®.</b> Lyrica®</p>
---	--	--	---

		<p><b>improved the way it produces many products</b>, substantially reducing waste, saving money, and winning recognition for its environmental efforts.</p> <p>Our Green Chemistry teams also actively collaborate to promote the principles of GC through a number of community outreach activities, including:</p> <ul style="list-style-type: none"> <li>• Onsite workshops and site visits for advanced undergraduate, graduate students, and their professors that highlight the contribution of Green Chemistry to sustainable product development</li> <li>• The development of a Green Chemistry teaching curriculum for middle school students (2004) to promote an early understanding of the role of chemistry in providing answers to environmental concerns</li> <li>• Active participation in international and local conferences, seminars and workshops through presentations on the role of Green Chemistry in a R&amp;D environment</li> </ul> <p><a href="http://www.pfizer.com/ehs/initiatives/green_chemistry.html">http://www.pfizer.com/ehs/initiatives/green_chemistry.html</a></p> <p><b>Green Buildings:</b> Pfizer has also embraced the opportunity to reduce environmental impacts associated with building construction and maintenance through the work performed by the Green Buildings Team.</p> <p>Pfizer is applying the green buildings principles of environmental design in new construction opportunities.</p> <p>Progress is also being made towards integrating environmental considerations into the renovation and maintenance of our existing buildings.</p> <p><a href="http://www.pfizer.com/ehs/initiatives/key_suppliers.html">http://www.pfizer.com/ehs/initiatives/key_suppliers.html</a></p>	<p>won the top European GC award—the <b>Excellence in Green Chemistry and Engineering Award</b>, and Vfend® was a <b>finalist for the Faraday award</b>.</p> <p>Pfizer's efforts to enhance the EHS profile of Viagra® were honored in 2003 with the receipt of the <b>UK Institute of Chemical Engineers (IChemE) "Crystal Faraday Award for Green Chemical Technology."</b> Pfizer reduced the amount of organic process wastes generated from 4,300 tons per year to only 300 tons per year.</p> <p>-Pfizer has earned <b>LEED™ (Leadership in Energy and Environmental Design) certification</b> for five projects, including the <b>company's first Silver-rated award</b> for its new construction of a research and development building in <b>New Haven, CT (USA)</b>. This facility was also the <b>first industry project to receive three (out of four) Green Globe certifications</b>.</p> <p>In 2006, Pfizer's <b>Ann Arbor B520 Renovation Project</b> Laboratories was recognized by the "<b>Labs for</b></p>
--	--	--	--

			<p><b>the 21st Century”</b> collaborative partnership project with the <b>U.S. Environmental Protection Agency and U.S. Department of Energy.</b></p> <p>- Pfizer New York Headquarters partners with a tile contractor who through an innovative ceiling tile milling and recycling process, <b>has reclaimed an average 250,000 square feet of ceiling tile per year.</b> Besides the recycling benefit, there is a <b>direct environmental benefit associated with non-landfill disposal.</b></p>
<p><b>ANTI-CORRUPTION</b></p>			
<p><b>Principle #10</b></p> <p>“Business should work against all forms of corruption, including extortion and bribery”</p>	<p>“Businesses must lead against corruption and call for a “level playing field.” This entails the integration of values, ethics and standards throughout the organization, such that every colleague actively upholds the highest standards.”</p>	<p><b>CONTEXT:</b> The UN Global Compact added this principle in 2004 (with the consent of its signatories) because corruption is a root cause of poor governance, lack of economic development and chronic poverty. Corruption can also be a barrier to access to health, which causes the suffering and death of many around the world.</p> <p>-Pfizer participated in the <b>Global Accountability Project</b>, a program of One World Trust. The Global Accountability Index measures four key criteria: <b>transparency</b> (provides accessible and timely information to stakeholders), <b>participation</b> (actively engages both internal and external stakeholders in decisions and activities that affect them), <b>evaluation</b> (processes through which an organization monitors and reviews its progress against goals and objectives) and <b>complaint and response</b> (means through which an organization enables stakeholders to file complaints on issues of non-compliance, or against decisions and actions).</p>	<p>-In 2006 Pfizer was ranked as one of the <b>most accountable global organizations</b> by <b>One World Trust’s Global Accountability Index.</b>  <a href="http://www.oneworldtrust.org/?display=programmes">http://www.oneworldtrust.org/?display=programmes</a></p> <p>-Pfizer serves on <b>Transparency International’s</b> Steering</p>

		<p>-In 2005 Pfizer adopted a <b>Global Policy on Interactions with Healthcare Professionals</b> that governs our pharmaceutical operations around the world including sales, marketing, medical and research and development. Our policy is based on the principles of maintaining ethics and compassion, building greater transparency and partnering to facilitate access to healthcare information and medicines.</p> <p>-Pfizer is committed to public policy engagement conducted in a legal and transparent manner. To demonstrate transparency we <b>publicly disclose our corporate political contributions</b> and employee <b>Political Action Committee contributions</b> on our website. The information is available at <a href="http://www.pfizer.com/pac">www.pfizer.com/pac</a>.</p> <p><b>-Business Roundtable’s S.E.E. Change Initiative</b> (Social.</p>	<p>Committee on Business Principles for Countering Bribery as well as the board of Transparency International USA.</p> <p>-In <b>Governance Metrics International’s (GMI)</b> August 2005 review, <b>Pfizer received the highest rating in the pharmaceutical &amp; biotechnology industry</b>—9.0 out of 10, well above average by GMI’s rating standards. <a href="http://www.pfizer.com/pfizer/subsites/corporate_citizenship/report/company_resp.jsp">http://www.pfizer.com/pfizer/subsites/corporate_citizenship/report/company_resp.jsp</a></p> <p>-The Global Policy applies to <b>Pfizer employees in every country</b> of operation and has been translated into 35 <b>languages</b>. <a href="http://pfizer.com/pfizer/subsites/corporate_citizenship/report/global_policy.jsp">http://pfizer.com/pfizer/subsites/corporate_citizenship/report/global_policy.jsp</a></p> <p>-Representatives from the <b>Nathan Cummings Foundation</b> have publicly stated that Pfizer’s political contributions report represents <b>the standard of disclosure to which other companies should aspire</b>.</p> <p>-Pfizer serves on the <b>Steering</b></p>
--	--	---	---

		<p>Environmental. Economic) promotes better business and a better world by encouraging members to adopt sustainability principles as a business planning tool and to showcase the results achieved. The initiative asks America's leading companies to set <b>challenging goals for environmental and social improvement</b> and to <b>meet these goals in a manner that creates business value.</b></p>	<p><b>Committee of the Business Roundtable's S.E.E. Initiative</b></p>
--	--	--	--